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Introduction
Breast cancer is the second leading cause of cancer death and is the most common cancer in women living in the US (1) . Breast cancer risk for both sporadic and familial breast cancer can be better elucidated in some women through the study of cancer risk in women from highrisk families. In 1994, BRCA1 was isolated (2) and it is now recognized that women with BRCAJ mutations have an increased risk of invasive breast and ovarian cancer. Specifically, inherited mutations in BRCA1 are associated with a 56-87% risk of breast cancer before the age of 70 (3, 4) , the lower estimate or risk representing an unselected population of individuals and the higher values are those with a strong family history of cancer. However, the determinants of why some women with mutations develop breast cancer (i.e. the penetrance) and others do not is mostly unknown. We hypothesize that genetic polymorphisms play an important role in both sporadic and hereditary breast cancer risk. The factors that regulate who actually gets breast cancer in women with highly penetrant mutations are only now being identified and it is possible that the same genetic traits and exposures trigger breast cancer in the general population; BRCA] mutation carriers are just substantially more susceptible to these gene-environment interactions. The study of penetrance in BRCA1 mutation carriers, therefore, might identify potential sporadic breast cancer risk factors and provide for prioritization for study in the general population. Although, it is generally believed that this is due to dietary, lifestyle and environmental exposures, heritable traits and genetic susceptibilities may play a significant role. There are countless genetic polymorphisms that may modulate hereditary and sporadic breast cancer risk, but little guidance on which ones to study. Many polymorphisms have been identified, but the relationship between the allelic variant and its possible change in protein function is usually unknown. This study will utilize a unique resource and capitalize on a high risk group of women to provide important information about high-risk and sporadic breast cancer. Specifically, this study will be able to answer these questions:
1. Why do only some women that harbor the BRCA1 mutation get breast cancer and others don't? 2. Are there polymorphisms in (involved in DNA repair) genes that increase susceptibility or modify breast cancer risk in this group? 3. How would this apply to sporadic breast cancer patients? Will that polymorphism increase risk of breast cancer in the general population?
The significance of this study lies in ascertaining how polymorphisms in DNA repair genes affect BRCA] penetrance and how this information could be applied to sporadic breast cancer. This will allow for prioritizing which genes to assess in epidemiological studies, and also provide an indication about which ones might have the greatest effect and interaction with BRCA]. The identified polymorphisms will then be tested in an existing epidemiological breast cancer study, a funded NIH and DOD case-control study of breast cancer from the University of Buffalo that studies the relationship between alcohol, diet, oxidative damage and sporadic breast cancer. Ultimately, these studies will identify susceptible groups of women and aid in the development of more rationale prevention strategies.
DNA repair and the DNA repair complex
Genes that affect BRCAJ mutation penetrance might be those involved in DNA repair, because BRCA1 is itself believed to be involved in DNA repair. At least four pathways of DNA repair operate on specific types of damaged DNA, and each pathway involves numerous molecules. BRCA1 is involved in double-stranded break repair; there are two different pathways involved in double-strand break repair: homology-directed repair or homologous recombinational repair (HR) and non-homologous end joining (NHEJ). In non-homologous end joining repair, the two double-strand-breaks are directly ligated. In HR, the DNA ends are first resected in the 5' to 3' direction by nucleases; the resulting 3' single-stranded tails then invade the DNA double helix of a homologous, undamaged partner molecule, and are extended by the action of DNA polymerase, which copies information from the partner.
BRCA1, BRCA2, and Rad5l
The function of BRCA1 remains under active study. Many studies have proven that loss of BRCA1 protein results in defective DNA damage repair, abnormal centrosome duplication, cell-cycle arrest, growth retardation, increased apoptosis, genetic instability, and tumorigenesis, suggesting a role in DNA repair. Evidence is mounting that BRCA1 has local activities at double-stranded break (DSB) sites. Specifically, BRCA1 has a role in sensing DNA damage and checkpoint control of the cell cycle. It has been suggested that BRCAI's role in sensing breaks actually controls homology-directed DNA repair (23) . In particular, BRCA1 is rapidly phosphorylated, by the kinases ATM and CHK2 after DNA damage in dividing cells, suggesting that it may work downstream of checkpoints that sense and signal DNA damage or problems with DNA replication during S phase (14) (15) (16) . After phosphorylation, BRCA1 migrates to the site of the DSB, and the MRE11/RAD50/NBS1 complex is recruited (12) . The exonucleolytic activity of the complex is mediated by MRE 11 and is responsible for resecting DSB ends to generate ssDNA tracts (22) . Recent work suggests that BRCA1 regulates the activity of this complex and under certain in vitro conditions, BRCA1 can inhibit the activity of MRE 11 (19), regulating the length and the persistence of ssDNA generation at sites of DNA breakage. Additionally, interaction of BRCA1 with BRCA2 was suggested by the discovery that both proteins interact with RAD51 (20, 21) . Whereas it seems that RAD51 interacts with BRCA2 directly, the association of BRCA1 with RAD51 may be indirect, perhaps mediated by BRCA2 (21) . The gene product of BRCA2 promotes and regulates the homologous recombination pathway of DNA double-strand-break repair (22) (23) (24) . RAD51 forms foci in the nucleus after irradiation and catalyzes strand exchange, an early step in homologous recombination that results in the formation of heteroduplex DNA molecules (25) . The three proteins (RAD51, BRCA1 and BRCA2) colocalize in irradiation induced foci (IRIF) and, notably, cells deficient in BRCA1 and BRCA2 are defective in RAD51 IRIF formation (26) (27) (28) (29) . Furthermore, it has also been shown that BRCA1 deficient embryonic stem cells have decreased homologous recombinational repair (30) .
BRCA2 has been linked to double-stranded DNA repair because of its interaction with Rad51, a RecA homologue in yeast whose function has been determined to be in homologydirected DNA repair. The regions that of BRCA2 that interact with Rad51 have been mapped to 8 BRC repeats (31) (32) (33) . The 8 repeats in BRCA2 appear to be redundant for Rad51 binding, because any of the repeats bind Rad51 efficiently.
The relationship between BRCA1, BRCA2, and Rad51 is still actively being investigated, and in the last year, many studies have elucidated this complex's role in homologous recombinational repair. Because of the possible consequences of genetic polymorphisms in BRCAI, BRCA2, and Rad51, such as protein functional changes, this study will only focus on genetic polymorphisms of those genes. Mutagen Sensitivity Assay and DNA repair Suboptimal or deficient repair of DNA damage may be a susceptibility factor predisposing women to breast cancer through increased sensitivity to carcinogenic damage from environmental exposures. The mutagen sensitivity assay, also known as the radiation-induced G2 chromatid assay, has been proposed as a phenotypic assay for cancer risk, including breast cancer (34). It is presumed that this assay is effective in measuring DNA repair capacity, at least in part. The assay measures defective DNA repair capacity by quantitating chromosomal breaks induced by gamma irradiation in cultured peripheral blood lymphocytes (PBL) (47, 48) . Although many mutagens such as bleomycin, x-rays, and UV light have been used in its place, gamma radiation has been used for breast cancer studies and triggers a variety of DNA damage relevant to this proposal. This assay, in small studies has been applied to high-risk families. For example, in cancer-prone individuals, cells display an abnormally high, at least two-fold higher number of breaks (49) . Also, Sanford et al have shown in several studies that more than 60 breaks and gaps per 100 metaphase cells, or 0.6 mean breaks and gaps per cell, is considered to be suboptimal repair (47, 50) . In another study, it was found that women at high risk (having 1 or more firstdegree relative with breast cancer) were 5 times more likely than controls to have suboptimal DNA repair (OR=5.2, 1.04-28.57). Deficient DNA repair was found in all women with breast cancer, but in only 32% of control women (p=0.02)(5 1).
Several groups doing the mutagen sensitivity assay have found a significantly increased incidence of sensitivity compared with controls. In one of the largest epidemiological studies, it was found that when bleomycin (BLM) was used, 97% of hereditary breast cancer cases, 30% of their family members, 44% of sporadic cases, and 21% of controls were either sensitive or hypersensitive (>0.8 mean breaks per cell) (52) . In other studies gamma radiation induced a higher degree of chromosomal damage in lymphocytes of family members of breast cancer patients compared with controls. In general, many other studies that have concluded ineffective DNA repair may be associated with cancer susceptibility in breast cancer patients and their firstdegree relatives (53-58). Table 1 lists all of the mutagen sensitivity studies relevant to this study. figure 5 and 6 ). Variations in slide readings within and between samples were also tested. Thirteen cell lines were tested in duplicate, triplicate, and quadruplicate. This was done in 2 ways: a) 2 sets of slides were made from the same culture; or cultures were grown on separate days, and mutagen sensitivity was performed on different days with different cultures. Either way, there was little intra-individual (within sample) variation, usually only different by 1 mean break per cell. There was some inter-individual (between samples), and adding to my hypothesis that there will be a range of mean breaks per cell between samples. Observations were also made on 3 EBV cell lines obtained from tissue culture. BRCA1 negative unaffected (sample #1036) grew the fastest; BRCA1 healthy mutation carrier grew (sample #631) the 2nd fastest; and BRCA1 affected mutation carrier (sample #481) grew slowest. These observations agree with previous literature that loss of BRCA1 leads to apoptosis and inhibition of cell growth.
Conclusions for Preliminary Experiments
1. The mutagen sensitivity assay is reproducible 2. EBV-immortalized cell lines grow at different rates depending on mutation and cancer status 3. 35 min hypotonic solution treatment ideal 4. 1 Oug/ul Colcemid solution at 1.5 hours showed best metaphases and revealed best information 5. 1 Gray is best treatment for cells 6. Cytogenetic student can give reliable results
Aim 1:
To identify DNA repair phenotypes in affected and healthy BRCA 1 mutation carriers that represent complex low penetrant genotypes by studying DNA repair proficiency in the terms of chromosomal breaks in EBV-immortalized lymphocytes following in vitro treatment with yirradiation.
Hypothesis 1:
There will be a range of responses, i.e. inter-individual variation, for chromosomal breaks using gamma irradiation among affected and unaffected women with BR CA 1 mutations.
Subjects:
The subjects in this study are confirmed BRCA1 mutation carriers recruited through the Lombardi Comprehensive Cancer Center -Familial Cancer Registry (LCCC-FCR). In this study, there are 99 affected and 54 are unaffected (healthy) BRCA1 mutation carriers. Peripheral blood lymphocytes were immortalized by EBV and stored in liquid nitrogen by our tissue culture core. Thirty-six patients without founder mutations (187delAG and 5382insC) had complete BRCA] and BRCA2 gene sequencing. Some patients are related (n=34). Patient demographics are listed on table 3. Figure 8 shows the age distribution in 65 unaffected and 95 healthy subjects. Mutagen Sensitivity: This project began by characterizing DNA repair capacity in healthy and affected subjects using immortalized lymphocytes and determining their sensitivity to mutagen exposure. The assay is called "mutagen sensitivity assay" and it is a marker of DNA repair. The mutagen sensitivity assay has been performed on 142 ebv-immortalized cell lines and all 19 fresh blood samples. In short, 1Gy radiation from a 137 Cs source gamma irradiator was used to induce chromosomal breakage according to the method developed by Sanford and Parshad (47, 62) . The culture medium used was RPMI1640 with L-glutamine. Fresh media was made once a week. Cultures were incubated for 4 hours to allow time for repair of breaks induced in the chromosomes. The cultures were then treated with colcemid to accumulate mitosis before harvesting. The cultures were then fixed, 4 slides per sample prepared (2-OGy and 2-1Gy), and stained with Giemsa. Chromosomal breaks were scored by microscopy. The frequency of chromatid breaks per cell (b/c) was calculated as a measure of an individual's DNA repair efficiency. Only chromatid breaks (discontinuity longer that the chromatid width) was scored. A minimum of 25 and a maximum of 50 metaphases per culture were scored. A diagrammatic representation of a few types gamma radiation-induced chromosomal breaks are shown in Figure  9 . The polymorphisms that are found to affect mutagen sensitivity will be used to determine if there is indeed a genotype that is associated with breast cancer risk. 
Results and Statistical Analysis:
The distribution of chromatid breaks are described in figure 10 . A frequency graph of 45 samples was plotted against the number of breaks. Only data analyzed is included in the figure. The independent variable is the frequency of mean breaks per cell and the dependent variable is breast cancer being affected or healthy and frequency. 
Mean Breaks per Cell

Conclusions for Hypothesis 1:
There are a range of responses in the patient population which agrees with hypothesis 1 50 far. A trend indicates affected BRCA1 mutation carriers have higher mean breaks per cell than healthy mutation carrers, but need larger sample size to be significant (n=69 in each group to detect difference).
Aim 2:
To identify single nucleotide polymorphisms (SNPs) in BRCA1, BRCA2, and Rad5l that are associated with defective DNA repair capacity in EBV-immortalized lymphocytes.
Hypothesis 2:
There will be polymorphisms in DNA repair genes (BRCA], BRCA2, Rad5]) that will affect the number of chromosomal breaks in affected and healthy BRCA1 mutation carriers
Genotype analysis: Polymorphisms worth characterizing and analyzing were identified in a preliminary study of sequencing data by Myriad Genetic Laboratories, Inc. in 36 patients without founder mutations (187delAG and 5382insC) and from the scientific literature and various webbased resources such as NIH's dbSNP and SNP500. PCR-based genotyping assays will be developed for BRCAI's P871L, E1038G, S1613G, K1183R, and BRCA2's H372N polymorphisms (see Table 4 ). SNP discovery in Rad51 will be done by direct sequencing of all 10 exons. These SNPs were chosen to be analyzed because they were the most frequently found SNPs in 36 BRCA1 mutation carriers and because they were found in an important region were an amino acid change could lead to change in the structure and function of the protein. For example, a couple BRCAI's and BRCA2's SNPs were found in the BRCT repeats of BRCA1 and BRC repeats of BRCA2, where Rad51 binds. DNA Extractions: DNA from 142 cell culture pellets has been extracted by the Qiagen M48 Biorobot (figure 11). In short, cell culture pellets were collected, washed in PBS, and stored in -20TC until time for extraction. All of the samples were carefully labeled and logged into a secure database. One day before extraction, approximately 2.0x10 6 cells were digested with lOuL of proteinase K, to degrade unwanted proteins and incubated in a 55°C water bath. After digestion, 150uL of PBS was added and samples were loaded in the M48 Biorobot (48 samples at a time). After extraction, DNA samples were quantitated by Genequant or Spectramax. Acceptable DNA:Protein (ratios) are 1.7-1.9, and if the quality was found to be outside these parameters, DNA was extracted again. After DNA was quantitated, aliquots of 50ug/ul, 1 Oug/ul, and 2ug/ul were made, labeled and logged into a secure database. Later, they will be adjusted for confounders. If these results cannot be normalized, the chi-squared test will be used used. SNPs to further assess in a case-control study will be determined by the results of statistical analysis. Sequencing of RadSl: PCR and sequencing is currently being performed on all 10 Rad51 exons. VariantSEQr Resequencing System primers were purchased from Applied Biosystems. The system is designed for resequencing the exons of genes implicated in cancer and various other complex diseases. VariantSEQr Resequencing System provides ready to use primer sets and a universal protocol for PCR, sequencing, and data analysis. In short, genomic DNA was amplified with a primer set, Amplitaq Gold PCR Master mix, ddH20, and 50% glycerol. The thermal cycler was programmed for activation at 96°C for 5 minutes, 40 cycles of amplification at 94°C for 30 seconds, 60°C for 45 seconds, and 72°C for 45 seconds. The final extension was done at 72°C for 10 minutes. After amplification, the sample is held at 4°C indefinitely.
After the PCR, the reaction was cleaned up using ExoSAP-it. In short, 4ul of ExoSAP-it was added to 10uL of PCR reaction. Then the reaction was centrifuged and placed in the thermal cycler for a program of 37°C for 30 minutes, 80°C for 15 minutes, and sample is held at 4°C indefinitely. After clean-up, the DNA is quantitated by running 3ul of sample against a DNA mass ladder on 2% agarose.
For sequencing, BigDye Terminator Reaction mix is added to 100ng/ul of clean DNA, M13 universal forward primer, and dH20. For this PCR reaction, the thermal cycler conditions are as follow: Denaturation at 96°C for 1 minute, 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds, and 60°C for 4 minutes. After amplification, the sample was held at 4°C indefinitely.
Reactions were then purified by spinning in a 96-well sephadex spin column. After purification, samples were then loaded into the MagaBace capillary sequencer (Figure 12 ), where specific parameters are loaded for each reaction plate. Results were analyzed initially using Bioedit, free software (http://www.mbio.ncsu.edu/BioEdit/bioedit.html), but will later be analysed using Sequencher. Results of Sequencing: I successfully amplified 5 exons of Rad5l in 96 samples (Figure 13 ). After many tries, the ABI protocol was optimized for the MegaBace capillary sequencer. Because my fragments are small (<300bp), a DNA concentration titration resulted in less DNA being used (25-50ng) . At 25ng/uL, good results were obtained on the MegaBace capillary sequencer (Figure 14) . 
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Abstract submitted to DOD and AACR DNA repair gene polymorphisms in hereditary and sporadic breast cancer Introduction: Breast cancer risk for both sporadic and familial breast cancer can better be elucidated in studies in women with BRCA1 mutations or in women in high risk breast/ovarian cancer families. Since the BRCA1 protein is involved in DNA repair, genotype-phenotype relationships can be established by the assessment of DNA repair efficiency and the identification of genetic polymorphisms in the BRCA1 DNA repair pathway. Objective: To study risks associated with certain polymorphisms in DNA repair genes, EBV-immortalized cells from women in the Lombardi Cancer Center Familial Registry were used in both a phenotypic assay that measures DNA repair capacity and genotypic assays that determined genotypes that increased susceptibility to breast cancer. Study Population: Ninety-nine affected and 54 unaffected BRCA] mutation carriers were analyzed in this study. There mean ages are 44 and 46, respectively (p=0.43). Methods: Gamma radiation was used to induce chromosomal breaks and those chromosomal breaks were scored, counted and compared within each patient and between patients. Also, the BRCA], BRCA2, and Rad5 genes were sequenced and the genotypes whose polymorphisms code for amino acid changes in conserved and functional areas were analyzed. We predict that polymorphisms in these genes will be highly correlated with deficient DNA repair in high risk breast cancer families. Results: We have found a difference in mean breaks per cell in cases versus controls. Also, several BRCA1 and BRCA2 polymorphisms appear to be associated with decreased DNA repair efficiency or high mean breaks per cell in our population. Specifically, the N372H (OR: 7.0 CI: 0.3-140.0) polymorphism in BRCA2, the K1 183R (OR: 1.8 CI:0.1-17.7) polymorphism in BRCA1, and the 5382insC mutation/ polymorphism (OR:3.0 CI:0.3-29.8), appear to be correlated with mutagen sensitivity, but a larger sample size is needed for odds ratios to be significant. In addition, we have a large population of 187delAG (n=54) and 5382insC (n=21) mutation carriers, so we can begin to look at what polymorphisms will affect risk within those mutation carriers., Conclusions: Ultimately, the study of the high risk families can inform, and set priorities for the study of genetic polymorphisms in sporadic breast cancer studies. These studies will identify susceptible groups of women and aid in the development of more rationale prevention strategies.
